A prospective study of statin use and poststroke depression

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 72-79

  Kim, Jae Min ^a   Stewart, Robert ^b   Kang, Hee Ju ^a   Bae, Kyung Yeol ^a   Kim, Sung Wan ^a   Shin, Il Seon ^a   Kim, Joon Tae ^a   Park, Man Seok ^a   Cho, Ki Hyun ^a   Yoon, Jin Sang ^a  

^a Chonnam National University Medical School   (South Korea)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; Longitudinal study; Statin; Stroke; Vascular diseases

Indexed keywords

ATORVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN;

ADULT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAMILTON SCALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTSTROKE DEPRESSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DEPRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891747157     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000051     Document Type: Review

References (41)

1. Morgan RE, Palinkas LA, Barrett-Connor EL, et al. Plasma cholesterol and depressive symptoms in older men. Lancet. 1993;341:75-79.
2. Aijanseppa S, Kivinen P, Helkala EL, et al. Serum cholesterol and depressive symptoms in elderly Finnish men. Int J Geriatr Psychiatry. 2002;17:629-634.
3. Blazer DG, Burchett BB, Fillenbaum GG. APOE e4 and low cholesterol as risks for depression in a biracial elderly community sample. Am J Geriatr Psychiatry. 2002;10:515-520.
4. Kim JM, Stewart R, Shin I-S, et al. Vascular disease /risk and late-life depression in a Korean community population. Br J Psychiatry. 2004;185:102-107.
5. Kim JM, Stewart R, Kim S-W, et al. Vascular risk factors and incident late-life depression in a Korean population. Br J Psychiatry. 2006;189:26-30.
6. Corti M-C, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med. 1997;126:753-760.
7. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-314.
8. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
9. Wardle J, Armitage J, Collins R, et al. Oxford Cholesterol Study Group. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ. 1996;313:75-78.
10. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108:538-546.
11. Stewart RA, Sharples KJ, North FM, et al. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med. 2000;160:3144-3152.
12. Ormiston T, Wolkowitz OM, Reus VI, et al. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics. 2003;44:412-414.
13. Yang C-C, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Int Med. 2003;163:1926-1932.
14. Feng L, Tan CH, Merchant RA, et al. Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort. Drugs Aging. 2008;25:795-805.
15. Young-Xu Y, Chan KA, Liao JK, et al. Long-term statin use and psychological well-being. J Am Coll Cardiol. 2003;42:690-697.
16. Otte C, Zhao S, Whooley MA. Statin use and risk of depression in patients with coronary heart disease: longitudinal data from the Heart and Soul Study. J Clin Psychiatry. 2012;73:610-615.
17. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757-767.
18. Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry. 2003;54:376-387.
19. Kim JM, Stewart R, Bae KY, et al. Serotonergic and BDNF genes and risk of depression after stroke. J Affect Disord. 2012;136:833-840.
20. Folstein MF, Fostein SE, McHugh PR. ''Mini-Mental State'': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
21. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-VI and ICD-10. J Clin Psychiatry. 1988;59:22-33.
23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
25. Salter K, Bhogal SK, Foley N, et al. The assessment of poststroke depression. Top Stroke Rehabil. 2007;14:1-24.
26. Yoo SW, Kim YS, Noh JS, et al. Validity of Korean version of the Mini-International Neuropsychiatric Interview. Anxiety Mood. 2006;20:50-55.
27. Oh SM, Min KJ, Park DB. A study on the standardization of the Hospital Anxiety and Depression Scale for Koreans: a comparison of normal, depressed and anxious groups. J Korean Neuropsychiatr Assoc. 1999;38:289-296.
28. Yi JS, Bae SO, Ahn YM, et al. Validity and reliability of the Korean version of the Hamilton Depression Rating Scale (K-HDRS). J Korean Neuropsychiatr Assoc. 2005;44:456-465.
29. Kim JM, Stewart R, Shin I-S, et al. Lifetime urban/rural residence, social support and late-life depression in Korea. Int J Geriatr Psychiatry. 2004;19:843-851.
30. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke. 1999;30:1534-1537.
31. Fazekas F, Chawluk JB, Alavi A, et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Roentgenol. 1987;149:351-356.
32. Prinz V, Endres M. The acute (cerebro)vascular effects of statins. Anesth Analg. 2009;109:572-584.
33. Glueck CJ, Tieger M, Kunkel R, et al. Improvement in symptoms of depression and in an index of life stressors accompanying treatment of severe hypertriglyceridemia. Biol Psychiatry. 1993;34:240-252.
34. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54:915-922.
35. Spalletta G, Bossu P, Ciaramella A, et al. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry. 2006;11:984-991.
36. Kim JM, Stewart R, Kim SW, et al. Associations of cytokine gene polymorphisms with post-stroke depression. World J Biol Psychiatry. 2012;13:579-587.
37. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
38. Vevera J, Fisar Z, Kvasnicka T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005;133:197-203.
39. N? Chro in?n D, Asplund K, A? sberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44:448-456.
40. Bhogal SK, Teasell R, Foley N, et al. Lesion location and poststroke depression. Systematic review of the methodological limitations in the literature. Stroke. 2004;35:794-802.
41. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL) trial. Arch Neurol. 2011;68:1245-1251.